logo-loader

Medibio attracts sophisticated investors

Published: 10:20 11 Oct 2017 AEDT

1507677741_australian-cash
The company's shares are in pre-open

Medibio Ltd (ASX:MEB) is pioneering the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions.

Earlier in the week the company entered into an agreement with Otsuka Pharmaceutical Development & Commercialization, Inc. to process clinical data.

Medibio is now preparing to outline a placement to professional and sophisticated investors, with the ASX granting a trading halt to prepare.

The halt will remain in place until the opening of trade on Friday 13th October 2017, or earlier if an announcement is made to the market.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

3 hours, 48 minutes ago